BAYER AG NA O.N.
Commented by André Will-Laudien on October 31st, 2022 | 13:31 CET
Top biotech shares - Now on the up: Bayer, Cardiol Therapeutics, BioNTech, Pfizer
The fight against the two "common diseases" of cancer and cardiovascular disease continues with a major infusion of resources. In early 2022, President Biden announced a new edition of the "Cancer Moonshot" and named new goals: To halve the cancer death rate within 25 years and significantly improve the lives of people with cancer. The most common cause of death in Germany, on the other hand, is cardiovascular disease. With around 338,000 deaths in 2020, it accounted for more than a third of the 985,500 deaths. The second most common cause of death was primarily cancer, followed by diseases of the respiratory system. The biotech industry thus continues to face major challenges. Who is well positioned?
Read
Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST
Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!
Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?
Read
Commented by Armin Schulz on September 14th, 2022 | 11:21 CEST
TUI, Almonty Industries, Bayer - Rebound after the sell-off?
Since September 8, the DAX has gained over 700 points despite inflation, a halt in Russian gas supplies and fears of recession. Inflation was 7.9% in August. The ECB's interest rate hike seems to have reassured many investors. The question remains whether the indices will again move to new highs. The S&P has broken its downward trend channel on a daily basis. No uptrend has been formed yet, but as long as the last lows are not broken again, it will continue to go up according to the chart technique. We therefore take a look at three companies that were recently sold off strongly and see whether there could be a sustainable rebound.
Read
Commented by Stefan Feulner on September 13th, 2022 | 11:34 CEST
BioNTech, Cardiol Therapeutics, Bayer - Caution, turnaround!
The market correction due to geopolitical uncertainties and fears of further interest rate hikes mainly affected growth stocks in recent months, with the capital-intensive biotech sector losing disproportionately. However, the industry is growing dynamically and will become increasingly important in the coming years in the fields of application of the pharmaceutical and chemical industry, in the agricultural and food sector and in environmental protection. Due to the market correction, there are currently enormous opportunities for a turnaround in selected stocks.
Read
Commented by Stefan Feulner on September 5th, 2022 | 10:58 CEST
Bayer, Almonty Industries, SAP - New opportunities after the sell-off
The scent of a perfect end to the week was in the air. Positive labor market data from the US drove global stock market indices, and Germany's leading index DAX went through the psychologically important 13,000-point mark like butter. But then came the gas shock with the announcement that Gazprom does not intend to ramp up gas deliveries via Nord Stream 1 again. And just like that, all the gains made dissolved into thin air. The DAX alone will likely start the new week today deep in the red at around 12,700 points. This threatens a new test of the year's lows, which in turn could allow new anticyclical entry opportunities in selected stocks.
Read
Commented by Stefan Feulner on September 1st, 2022 | 10:26 CEST
K+S AG, BrainChip, Bayer - Shares in waiting position
At the end of last week, FED head Jerome Powell brought down the stock markets with the announcement of further interest rate steps and a hawkish stance by the US Federal Reserve. A similar scenario looms next week at the European Central Bank meeting. Here, speculation is mounting that an interest rate step of even 0.75% could be imminent due to rampant inflation. In the long term, however, the contingent of the European monetary guardians is limited because too strong an increase would lead to the collapse of the debt countries. Moreover, this would mean a further slowdown of the already weakening European economy. Therefore, a return to the loose monetary policy in the fourth quarter does not appear to be out of the question, which could result in a further stock market boom.
Read
Commented by Carsten Mainitz on August 31st, 2022 | 13:35 CEST
BYD, Kleos Space, Bayer - Great opportunities in laggards
Although stock markets continue to correct, driven by geopolitical uncertainties and interest rate fears, some sectors have defied the generally adverse market conditions in recent weeks. For example, renewable energy stocks such as Plug Power more than doubled on the back of Joe Biden's climate change package. However, most companies from other sectors remain at discounted levels despite excellent prospects, which should offer investors good long-term entry opportunities.
Read
Commented by Stefan Feulner on August 9th, 2022 | 12:36 CEST
Buy after the price slide? Tocvan Ventures, Palantir, Bayer
The stock markets have continued to move upwards since their lows in mid-June, with the DAX easily breaking the 13,600 mark. The precious metals and crypto markets also look sunnier in the hot August. One reason for the good mood, in addition to the pleasant temperatures, is the positive course of the reporting season for the second quarter. Still, there are outliers to the downside that represent a potential long-term buying opportunity despite below-forecast numbers.
Read
Commented by Stefan Feulner on June 23rd, 2022 | 10:14 CEST
ThyssenKrupp, Desert Gold, Bayer - Waiting for the turnaround
After a strong start to the week for the DAX and a high of 13,444 points, the leading German index ran out of steam. Due to increasing fears of a recession and concerns about continued enormously high inflation rates, the stock market barometer again fell below the psychologically important mark of 13,000 points. The speech of the head of the US Federal Reserve, Jerome Powell, should therefore be enormously important for the further course and provide for volatile markets. A decision is also likely to be made soon on the gold market based on the strategy of the monetary guardians.
Read
Commented by Nico Popp on June 22nd, 2022 | 13:01 CEST
Crisis investments? Pharmaceutical stocks in check: Bayer, XPhyto, Pfizer
Many investors want solid foundations for their portfolios when the market is in turmoil. Pharmaceutical stocks have always been considered largely detached from the overall market - after all, our health is not subject to market cycles. We explain whether this assumption is correct and how investors can now invest in stocks from the sector, using three shares as examples.
Read